Why the study?
Genetic variations in CYP2C19 may influence response to clopidogrel therapy, but their prevalence and clinical impact with a doubled maintenance dose were not established in Syrian patients with CAD following PCI.
Does a doubled maintenance dose of clopidogrel (150 mg/day) mitigate the impact of CYP2C19 variants on clinical outcomes in Syrian CAD patients following PCI?
Population
50 Syrian CAD patients on DAPT following PCI
Comparison
CYP2C19 variants and metabolizer phenotypes on doubled maintenance dose clopidogrel
Design
Observational cohort study
Follow-up
18-24 months
Authors
Loading...
Should not yet change post-PCI DAPT; leaves open whether 150 mg clopidogrel offsets CYP2C19*2-related ischemic risk.
Does a doubled maintenance dose of clopidogrel (150 mg/day) mitigate the impact of CYP2C19 variants on clinical outcomes in Syrian CAD patients following PCI?
A doubled maintenance dose of clopidogrel (150 mg/day) may mitigate the variability in clinical response due to CYP2C19*2 carrier status in Syrian patients undergoing PCI.
L. Youssef (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: